Evaluating Effectiveness and Long Term Safety of Damoctocog Alfa Pegol in Patients, Who Have Been Diagnosed With Hemophilia A

Inclusion Criteria: * Diagnosis of hemophilia A. * Patients previously treated for Hemophilia A. * Patients without previous history of inhibitors or patients with previous history of inhibitors on standard prophylaxis therapy for at least 1 year prior to study entry. * No current evidence of FVIII inhibitor or clinical suspicion of FVIII inhibitor. * Initiation of or currently on damoctocog alfa pegol with any kind of treatment modality (on-demand, prophylaxis, or intermittent prophylaxis). * Signed informed consent/assent. Exclusion Criteria: * Concurrent participation in an investigational program with interventions outside of routine clinical practice. * Diagnosis of any other bleeding/coagulation disorder other than hemophilia A. * Contra-indications according to the local marketing authorization. * Patient on immune tolerance induction (ITI) treatment at the time of enrollment.